Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies
The Lancet Oncology, Volume 10, No. 8, Year 2009
Notification
URL copied to clipboard!
Description
Background: Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer. Methods: Individual data on 7946 cases and 7888 controls from 49 different studies worldwide were reanalysed. Odds ratios (OR) were estimated using logistic regression, stratifying by study and ethnic origin. Subgroup analyses were done for infection with HPV, ethnic origin, Hardy-Weinberg equilibrium, study quality, and the material used to determine TP53 genotype. Findings: The pooled estimates (OR) for invasive cervical cancer were 1·22 (95% CI 1·08-1·39) for arginine homozygotes compared with heterozygotes, and 1·13 (0·94-1·35) for arginine homozygotes versus proline homozygotes. Subgroup analyses showed significant excess risks only in studies where controls were not in Hardy-Weinberg equilibrium (1·71 [1·21-2·42] for arginine homozygotes compared with heterozygotes), in non-epidemiological studies (1·35 [1·15-1·58] for arginine homozygotes compared with heterozygotes), and in studies where TP53 genotype was determined from tumour tissue (1·39 [1·13-1·73] for arginine homozygotes compared with heterozygotes). Null results were noted in studies with sound epidemiological design and conduct (1·06 [0·87-1·29] for arginine homozygotes compared with heterozygotes), and studies in which TP53 genotype was determined from white blood cells (1·06 [0·87-1·29] for arginine homozygotes compared with heterozygotes). Interpretation: Subgroup analyses indicated that excess risks were most likely not due to clinical or biological factors, but to errors in study methods. No association was found between cervical cancer and TP53 codon 72 polymorphism when the analysis was restricted to methodologically sound studies. Funding: German Research Foundation (DFG). © 2009 Elsevier Ltd. All rights reserved.
Authors & Co-Authors
Klug, Stefanie J.
Germany, Mainz
Johannes Gutenberg-universität Mainz
Ressing, Meike
Germany, Mainz
Johannes Gutenberg-universität Mainz
Koenig, Jochem
Germany, Mainz
Johannes Gutenberg-universität Mainz
Abba, Martin C.
Argentina, La Plata
Universidad Nacional de la Plata
Agorastos, Theodoros
Greece, Thessaloniki
Aristotle University of Thessaloniki
Brenna, Sylvia MF
Brazil, Sao Paulo
Universidade Cidade de São Paulo
Ciotti, Marco
Italy, Rome
Policlinico Tor Vergata
Das, BR R.
India, Mumbai
Super Religare Laboratories Ltd.
Del Mistro, Annarosa
Italy, Padua
Istituto Oncologico Veneto Iov - Irccs
Dybikowska, Aleksandra
Poland, Gdansk
Gdanski Uniwersytet Medyczny
Giuliano, Anna Regina
United States, Tampa
Moffitt Cancer Center
Gudlevičienė, Živilė
Lithuania, Vilnius
Vilniaus Universitetas
Gyllensten, Ulf B.
Sweden, Uppsala
Rudbecklaboratoriet
Haws, Andrea LF
United States, Houston
Baylor College of Medicine
Helland, Åslaug
Norway, Oslo
Rikshospitalet-radiumhospitalet hf
Herrington, C. S.
United Kingdom, St Andrews
University of st Andrews
Hildesheim, Allan
United States, Rockville
National Cancer Institute Nci
Humbey, Olivier
France, Besancon
Université de Franche-comté
Jee, Sunha
South Korea, Seoul
Yonsei University
Kim, Jae Weon
South Korea, Seoul
Seoul National University
Madeleine, Margaret M.
United States, Seattle
Fred Hutchinson Cancer Research Center
Menczer, Joseph
Israel, Tel Aviv-yafo
Gynecologic Oncology Unit
Ngan, Hextan Yuen Sheung
Hong Kong
Queen Mary Hospital Hong Kong
Nishikawa, Akira
Japan, Tokyo
Nippon Telegraph and Telephone East Corporation
Niwa, Yoshimitsu
Japan, Nisshin
Niwa Clinic
Pegoraro, Rosemary J.
South Africa, Durban
The Nelson R. Mandela Medical School
Pillai, MR R.
India, Thiruvananthapuram
Rajiv Gandhi Centre for Biotechnology
Ranzani, Gulielmina
Italy, Pavia
Università Degli Studi Di Pavia
Rezza, Giovanni
Italy, Rome
Istituto Superiore Di Sanita
Rosenthal, Adam N.
United Kingdom, London
University College London
Roychoudhury, Susanta
India, Kolkata
Indian Institute of Chemical Biology
Saranath, Dhananjaya M.
India, Navi Mumbai
Reliance Life Science Pvt. Ltd.
Schmitt, Virginia M.
Brazil, Porto Alegre
Pontifícia Universidade Católica do Rio Grande do Sul
Sengupta, Sharmila B.
India, Kolkata
Indian Statistical Institute, Kolkata
Settheetham-Ishida, Wannapa
Thailand, Khon Kaen
Faculty of Medicine, Khon Kaen University
Shirasawa, Hiroshi
Japan, Chiba
Chiba University
Snijders, Peter Jf
Netherlands, Amsterdam
Amsterdam Umc - Vrije Universiteit Amsterdam
Stoler, M. H.
United States, Charlottesville
University of Virginia School of Medicine
Suárez-Rincón, Angel E.
Mexico, Mexico
Instituto Mexicano Del Seguro Social
Szarka, Krisztina
Hungary, Debrecen
Általános Orvostudományi Kar
Tachezy, Ruth
Czech Republic, Prague
Institute of Hematology and Blood Transfusion
Ueda, Masatsugu
Japan, Osaka
Osaka Cancer Prevention and Detection Center
Van Der Zee, Ate Gj
Netherlands, Groningen
Universitair Medisch Centrum Groningen
von Knebel-Doeberitz, Magnus
Germany, Heidelberg
Universitätsklinikum Heidelberg
Wu, Ming Tsang
Taiwan, Kaohsiung
Kaohsiung Medical University Chung-ho Memorial Hospital
Yamashita, Tsuyoshi
Japan, Hakodate
Hakodate Municipal Hospital
Zehbe, Ingeborg
Canada, Thunder Bay
Thunder Bay Regional Hospital
Blettner, Maria
Germany, Mainz
Johannes Gutenberg-universität Mainz
Statistics
Citations: 48
Authors: 48
Affiliations: 45
Identifiers
Doi:
10.1016/S1470-2045(09)70187-1
ISSN:
14702045
Research Areas
Cancer
Genetics And Genomics
Participants Gender
Female